Revvity Partners with Eli Lilly to Launch AI Drug Discovery Platform
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 09 2026
0mins
Should l Buy LLY?
Source: NASDAQ.COM
- Collaborative Innovation: Revvity's partnership with Eli Lilly integrates Lilly's AI-driven predictive modeling platform, Lilly TuneLab, into the Revvity Signals platform, aiming to expand access to advanced AI tools for drug discovery and enhance research efficiency.
- Data Security Assurance: The collaboration establishes a scalable federated framework that allows biotech companies to apply Lilly's predictive models to their research programs while keeping proprietary data private and secure, ensuring both data confidentiality and research flexibility.
- Funding Support Initiative: Revvity and Lilly will jointly fund access for selected participants, including the use of Signals One and Signals Xynthetica software along with modeling credits, aiming to lower barriers to AI adoption across the biotech sector and promote technology proliferation.
- Integration Advantage: Lilly TuneLab offers AI and machine learning models trained on decades of Lilly research data, enhanced through federated learning, while Revvity's Signals platform integrates these models into existing scientific workflows, significantly boosting overall drug discovery efficiency.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LLY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LLY
Wall Street analysts forecast LLY stock price to rise
20 Analyst Rating
18 Buy
2 Hold
0 Sell
Strong Buy
Current: 1021.410
Low
950.00
Averages
1192
High
1500
Current: 1021.410
Low
950.00
Averages
1192
High
1500
About LLY
Eli Lilly and Company is a medicine company, which discovers, develops, manufactures, and market products in a single business segment called human pharmaceutical products. The Company manufacture and distribute its products through facilities in the United States, including Puerto Rico, and in Europe and Asia. The Company’s products are sold in approximately 90 countries. Its Cardiometabolic Health products Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound, and others. Its oncology products include Cyramza, Erbitux, Tyvyt, Verzenio, Retevmo, Jaypirca, and others. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. Its LillyDirect, a direct-to-patient digital health care platform, provides delivery of select Lilly medicines dispensed by third-party pharmacies to patients.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Eli Lilly's Acquisition of Engage Biologics Advances Gene Therapy Development
- Acquisition Strategy: Eli Lilly's $202 million acquisition of Engage Biologics marks its seventh acquisition this year, further expanding its footprint in the gene therapy sector and demonstrating the company's commitment to the future of genetic medicine.
- Technological Innovation: Engage Biologics is developing the Tethosome platform, which aims to address critical challenges such as immune sensing and cellular delivery efficiency by combining engineered DNA payloads, lipid nanoparticle delivery, and proprietary mRNA components, thereby enhancing the potency and tolerability of gene therapies.
- Market Outlook: Following the acquisition of Engage, Eli Lilly is expected to bolster its product pipeline in oncology, autoimmune diseases, and CAR-T therapies, especially with the upcoming clinical trial results for its diabetes drug Retatrutide, which has kept market attention on its stock.
- Investor Sentiment: Despite LLY shares rising about 1% over the past year, retail investor sentiment remains bearish, particularly ahead of the anticipated Retatrutide trial results, indicating a divergence in market expectations for the company's future performance.
See More
Eli Lilly Accuses Church Leaders of $200 Million Fraud Scheme
- Fraud Allegations: Eli Lilly has filed a lawsuit in Miami federal court accusing DrugPlace and Community Health of stealing over $200 million in rebates for the diabetes drug Trulicity through a fraudulent scheme that has lasted six years, severely impacting the company's financial standing.
- False Drug Distribution: The lawsuit claims DrugPlace falsely distributed Trulicity by alleging it was dispensed to church members while actually reselling the drug on the secondary market, thereby profiting illegally while collecting rebates, highlighting the fraudulent nature of their business model.
- Data Analysis Revelation: Lilly's data analysis revealed that all Trulicity prescriptions submitted had identical quantities and supply periods with almost no refills or reversals, indicating systemic fraud that further tarnishes the company's reputation and trust in its rebate processes.
- Legal Action: Lilly is seeking a temporary restraining order and preliminary injunction to prevent the defendants from continuing their fraudulent activities while also suing church leaders involved, demonstrating the company's commitment to maintaining market integrity and protecting patient access to its medications.
See More
Eli Lilly Accuses Church Leaders of $200M Fraud Scheme
- Fraud Allegations: Eli Lilly has filed a lawsuit in federal court in Miami, accusing several church bishops of being involved in a rebate fraud scheme that has cost the company over $200 million, highlighting vulnerabilities in its drug rebate management.
- False Claims Mechanism: The lawsuit alleges that DrugPlace pharmacy falsely claimed to dispense Trulicity to church members while actually reselling the drug on the secondary market, revealing serious misconduct within the pharmaceutical distribution chain.
- Inflated Membership Numbers: Lilly pointed out that DrugPlace claimed the church had 7 million members, while a Pew Research Center survey in 2025 estimated the actual number to be around 1.9 million, indicating that this false data not only compromised the legitimacy of rebate claims but also reflects regulatory failures in the drug market.
- Legal Action: Eli Lilly is seeking a temporary restraining order and preliminary injunction to prevent the defendants from continuing fraudulent activities while protecting patient access to its medications, demonstrating the company's strong commitment to maintaining market integrity.
See More
Eli Lilly Acquires Engage Biologics for Up to $202M
- Acquisition Deal: Eli Lilly announced the acquisition of Engage Biologics for up to $202 million in cash, which includes upfront and milestone-based payments, reflecting strong interest in advancing non-viral genetic medicine development.
- Technology Platform: Founded in 2021, Engage Biologics focuses on the Tethosome platform, a non-viral DNA delivery system designed to effectively deliver DNA payloads to human tissues, leveraging lipid nanoparticle and mRNA technology with significant potential applications.
- CEO Statement: Engage Bio CEO Will Olsen expressed pride in the rapid progress made towards a new class of genetic medicines despite the company's lean structure and modest funding, emphasizing that the combination with Lilly will accelerate the development of new therapies.
- Strategic Implications: This acquisition not only enhances Eli Lilly's technological capabilities in the gene therapy space but also has the potential to drive future product line expansion and market competitiveness by integrating Engage's innovative platform.
See More
Market Volatility and Interest Rate Impact
- Market Dynamics: On Tuesday, the market dipped slightly, with the S&P 500 on track for its third consecutive decline, primarily due to a rotation from AI-related stocks into software, although this trend lost momentum as the day progressed, exemplified by Salesforce's stock rising by $8 to $187 before turning negative, indicating fragile market sentiment.
- Rising Interest Rates: High energy prices, driven by uncertainty surrounding the Strait of Hormuz and the Iran conflict, have led to inflation fears rippling through the bond market, with the 10-year Treasury yield climbing to 4.665% and the 30-year yield hitting 5.19%, the highest level in nearly 19 years, which could suppress consumer spending and slow economic growth.
- Pharmaceutical Outlook: A Citigroup survey revealed that about 50% of surveyed endocrinologists expect oral GLP-1 medications to attract new patients, with many previously discontinued injectable users considering a return to oral options, positively supporting Eli Lilly's Foundayo drug's market growth prospects, with projected sales hitting $2.8 billion by 2026, significantly above the consensus estimate of $1.5 billion.
- Google Developer Conference: During the Google I/O developer conference, CEO Sundar Pichai announced that monthly active users of the Gemini AI app have exceeded 900 million, with daily requests increasing more than sevenfold, although Alphabet's shares fell over 1% in afternoon trading, the introduction of new AI features like Gmail Live and Doc Live demonstrates Google's ongoing innovation in AI, which may positively impact future market performance.
See More
Hims Expands Debt Offering to Support Acquisition
- Debt Offering Expansion: Hims & Hers increased its convertible debt offering from $300 million to $350 million, expecting net proceeds of $338.5 million to fund the proposed Eucalyptus acquisition and AI healthcare expansion, despite a 11% stock drop on Monday indicating market concerns about financial health.
- Acquisition Plans: The company plans to acquire Eucalyptus for up to $1.15 billion, which is expected to expand its operations into Australia, Japan, Canada, Germany, and the UK, enhancing its ability to deliver localized healthcare services to over 775,000 customers served by Eucalyptus.
- AI Healthcare Strategy: Hims recently launched Labs AI, an AI healthcare assistant integrated into its platform that can analyze up to 130 biomarkers, helping users interpret lab tests and health risks, showcasing the company's rapid expansion and investment in AI healthcare technology.
- Product Diversification: Hims has moved beyond telehealth prescriptions with the launch of Testosterone Rx+, a daily hormone-support pill, and partnerships with Novo Nordisk and Eli Lilly to offer branded therapies, reflecting its strategic vision for expanding healthcare choices and accessibility.
See More
Eli Lilly's Acquisition of Engage Biologics Advances Gene Therapy Development
- Acquisition Strategy: Eli Lilly's $202 million acquisition of Engage Biologics marks its seventh acquisition this year, further expanding its footprint in the gene therapy sector and demonstrating the company's commitment to the future of genetic medicine.
- Technological Innovation: Engage Biologics is developing the Tethosome platform, which aims to address critical challenges such as immune sensing and cellular delivery efficiency by combining engineered DNA payloads, lipid nanoparticle delivery, and proprietary mRNA components, thereby enhancing the potency and tolerability of gene therapies.
- Market Outlook: Following the acquisition of Engage, Eli Lilly is expected to bolster its product pipeline in oncology, autoimmune diseases, and CAR-T therapies, especially with the upcoming clinical trial results for its diabetes drug Retatrutide, which has kept market attention on its stock.
- Investor Sentiment: Despite LLY shares rising about 1% over the past year, retail investor sentiment remains bearish, particularly ahead of the anticipated Retatrutide trial results, indicating a divergence in market expectations for the company's future performance.
See More
Eli Lilly Accuses Church Leaders of $200 Million Fraud Scheme
- Fraud Allegations: Eli Lilly has filed a lawsuit in Miami federal court accusing DrugPlace and Community Health of stealing over $200 million in rebates for the diabetes drug Trulicity through a fraudulent scheme that has lasted six years, severely impacting the company's financial standing.
- False Drug Distribution: The lawsuit claims DrugPlace falsely distributed Trulicity by alleging it was dispensed to church members while actually reselling the drug on the secondary market, thereby profiting illegally while collecting rebates, highlighting the fraudulent nature of their business model.
- Data Analysis Revelation: Lilly's data analysis revealed that all Trulicity prescriptions submitted had identical quantities and supply periods with almost no refills or reversals, indicating systemic fraud that further tarnishes the company's reputation and trust in its rebate processes.
- Legal Action: Lilly is seeking a temporary restraining order and preliminary injunction to prevent the defendants from continuing their fraudulent activities while also suing church leaders involved, demonstrating the company's commitment to maintaining market integrity and protecting patient access to its medications.
See More
Eli Lilly Accuses Church Leaders of $200M Fraud Scheme
- Fraud Allegations: Eli Lilly has filed a lawsuit in federal court in Miami, accusing several church bishops of being involved in a rebate fraud scheme that has cost the company over $200 million, highlighting vulnerabilities in its drug rebate management.
- False Claims Mechanism: The lawsuit alleges that DrugPlace pharmacy falsely claimed to dispense Trulicity to church members while actually reselling the drug on the secondary market, revealing serious misconduct within the pharmaceutical distribution chain.
- Inflated Membership Numbers: Lilly pointed out that DrugPlace claimed the church had 7 million members, while a Pew Research Center survey in 2025 estimated the actual number to be around 1.9 million, indicating that this false data not only compromised the legitimacy of rebate claims but also reflects regulatory failures in the drug market.
- Legal Action: Eli Lilly is seeking a temporary restraining order and preliminary injunction to prevent the defendants from continuing fraudulent activities while protecting patient access to its medications, demonstrating the company's strong commitment to maintaining market integrity.
See More
Eli Lilly Acquires Engage Biologics for Up to $202M
- Acquisition Deal: Eli Lilly announced the acquisition of Engage Biologics for up to $202 million in cash, which includes upfront and milestone-based payments, reflecting strong interest in advancing non-viral genetic medicine development.
- Technology Platform: Founded in 2021, Engage Biologics focuses on the Tethosome platform, a non-viral DNA delivery system designed to effectively deliver DNA payloads to human tissues, leveraging lipid nanoparticle and mRNA technology with significant potential applications.
- CEO Statement: Engage Bio CEO Will Olsen expressed pride in the rapid progress made towards a new class of genetic medicines despite the company's lean structure and modest funding, emphasizing that the combination with Lilly will accelerate the development of new therapies.
- Strategic Implications: This acquisition not only enhances Eli Lilly's technological capabilities in the gene therapy space but also has the potential to drive future product line expansion and market competitiveness by integrating Engage's innovative platform.
See More
Market Volatility and Interest Rate Impact
- Market Dynamics: On Tuesday, the market dipped slightly, with the S&P 500 on track for its third consecutive decline, primarily due to a rotation from AI-related stocks into software, although this trend lost momentum as the day progressed, exemplified by Salesforce's stock rising by $8 to $187 before turning negative, indicating fragile market sentiment.
- Rising Interest Rates: High energy prices, driven by uncertainty surrounding the Strait of Hormuz and the Iran conflict, have led to inflation fears rippling through the bond market, with the 10-year Treasury yield climbing to 4.665% and the 30-year yield hitting 5.19%, the highest level in nearly 19 years, which could suppress consumer spending and slow economic growth.
- Pharmaceutical Outlook: A Citigroup survey revealed that about 50% of surveyed endocrinologists expect oral GLP-1 medications to attract new patients, with many previously discontinued injectable users considering a return to oral options, positively supporting Eli Lilly's Foundayo drug's market growth prospects, with projected sales hitting $2.8 billion by 2026, significantly above the consensus estimate of $1.5 billion.
- Google Developer Conference: During the Google I/O developer conference, CEO Sundar Pichai announced that monthly active users of the Gemini AI app have exceeded 900 million, with daily requests increasing more than sevenfold, although Alphabet's shares fell over 1% in afternoon trading, the introduction of new AI features like Gmail Live and Doc Live demonstrates Google's ongoing innovation in AI, which may positively impact future market performance.
See More
Hims Expands Debt Offering to Support Acquisition
- Debt Offering Expansion: Hims & Hers increased its convertible debt offering from $300 million to $350 million, expecting net proceeds of $338.5 million to fund the proposed Eucalyptus acquisition and AI healthcare expansion, despite a 11% stock drop on Monday indicating market concerns about financial health.
- Acquisition Plans: The company plans to acquire Eucalyptus for up to $1.15 billion, which is expected to expand its operations into Australia, Japan, Canada, Germany, and the UK, enhancing its ability to deliver localized healthcare services to over 775,000 customers served by Eucalyptus.
- AI Healthcare Strategy: Hims recently launched Labs AI, an AI healthcare assistant integrated into its platform that can analyze up to 130 biomarkers, helping users interpret lab tests and health risks, showcasing the company's rapid expansion and investment in AI healthcare technology.
- Product Diversification: Hims has moved beyond telehealth prescriptions with the launch of Testosterone Rx+, a daily hormone-support pill, and partnerships with Novo Nordisk and Eli Lilly to offer branded therapies, reflecting its strategic vision for expanding healthcare choices and accessibility.
See More
